Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 47

1.

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.

Harris LN, Ismaila N, McShane LM, Andre F, Collyar DE, Gonzalez-Angulo AM, Hammond EH, Kuderer NM, Liu MC, Mennel RG, Van Poznak C, Bast RC, Hayes DF; American Society of Clinical Oncology..

J Clin Oncol. 2016 Apr 1;34(10):1134-50. doi: 10.1200/JCO.2015.65.2289. Epub 2016 Feb 8. Review.

2.

Cisplatin resistance in gastric cancer cells is associated with HER2 upregulation-induced epithelial-mesenchymal transition.

Huang D, Duan H, Huang H, Tong X, Han Y, Ru G, Qu L, Shou C, Zhao Z.

Sci Rep. 2016 Feb 5;6:20502. doi: 10.1038/srep20502.

3.

Integrating genetics and epigenetics in breast cancer: biological insights, experimental, computational methods and therapeutic potential.

Cava C, Bertoli G, Castiglioni I.

BMC Syst Biol. 2015 Sep 21;9:62. doi: 10.1186/s12918-015-0211-x. Review.

4.

The role of HER-2 in Breast Cancer.

Ishikawa T, Ichikawa Y, Shimizu D, Sasaki T, Tanabe M, Chishima T, Takabe K, Endo I.

J Surg Sci. 2014 Dec;2(1):4-9. No abstract available.

5.

Topoisomerase II alpha and TLE3 as predictive markers of response to anthracycline and taxane-containing regimens for neoadjuvant chemotherapy in breast cancer.

Susini T, Berti B, Carriero C, Tavella K, Nori J, Vanzi E, Molino C, Di Tommaso M, Santini M, Saladino V, Bianchi S.

Onco Targets Ther. 2014 Nov 17;7:2111-20. doi: 10.2147/OTT.S71646. eCollection 2014.

6.
7.

Dissecting GRB7-mediated signals for proliferation and migration in HER2 overexpressing breast tumor cells: GTP-ase rules.

Pradip D, Bouzyk M, Dey N, Leyland-Jones B.

Am J Cancer Res. 2013 Apr 3;3(2):173-95. Print 2013.

8.

Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab.

Fountzilas G, Christodoulou C, Bobos M, Kotoula V, Eleftheraki AG, Xanthakis I, Batistatou A, Pentheroudakis G, Xiros N, Papaspirou I, Koumarianou A, Papakostas P, Bafaloukos D, Skarlos DV, Kalogeras KT.

J Transl Med. 2012 Oct 23;10:212. doi: 10.1186/1479-5876-10-212.

9.

Pathological tumor response to neoadjuvant chemotherapy using anthracycline and taxanes in patients with triple-negative breast cancer.

Sakuma K, Kurosumi M, Oba H, Kobayashi Y, Takei H, Inoue K, Tabei T, Oyama T.

Exp Ther Med. 2011 Mar;2(2):257-264. Epub 2011 Jan 20.

10.

Prognostic significance of TOP2A gene dosage in HER-2-negative breast cancer.

Zaczek AJ, Markiewicz A, Seroczynska B, Skokowski J, Jaskiewicz J, Pienkowski T, Olszewski WP, Szade J, Rhone P, Welnicka-Jaskiewicz M, Jassem J.

Oncologist. 2012;17(10):1246-55. doi: 10.1634/theoncologist.2012-0023. Epub 2012 Aug 7.

11.

Distinct genes related to drug response identified in ER positive and ER negative breast cancer cell lines.

Shen K, Rice SD, Gingrich DA, Wang D, Mi Z, Tian C, Ding Z, Brower SL, Ervin PR Jr, Gabrin MJ, Tseng G, Song N.

PLoS One. 2012;7(7):e40900. doi: 10.1371/journal.pone.0040900. Epub 2012 Jul 16.

12.

Poor-prognosis estrogen receptor- positive disease: present and future clinical solutions.

Lønning PE.

Ther Adv Med Oncol. 2012 May;4(3):127-37. doi: 10.1177/1758834012439338.

13.

A target based approach identifies genomic predictors of breast cancer patient response to chemotherapy.

Hallett RM, Pond G, Hassell JA.

BMC Med Genomics. 2012 May 11;5:16. doi: 10.1186/1755-8794-5-16.

14.

Combined experimental and computational analysis of DNA damage signaling reveals context-dependent roles for Erk in apoptosis and G1/S arrest after genotoxic stress.

Tentner AR, Lee MJ, Ostheimer GJ, Samson LD, Lauffenburger DA, Yaffe MB.

Mol Syst Biol. 2012 Jan 31;8:568. doi: 10.1038/msb.2012.1.

15.

TOP2A amplification in the absence of that of HER-2/neu: toward individualization of chemotherapeutic practice in breast cancer.

Glynn RW, Mahon S, Curran C, Callagy G, Miller N, Kerin MJ.

Oncologist. 2011;16(7):949-55. doi: 10.1634/theoncologist.2011-0071. Epub 2011 Jun 24.

16.

Assessment of Topoisomerase II α status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization.

Romero A, Martín M, Cheang MC, López García-Asenjo JA, Oliva B, He X, de la Hoya M, García Sáenz JÁ, Arroyo Fernández M, Díaz Rubio E, Perou CM, Caldés Llopis T.

Am J Pathol. 2011 Apr;178(4):1453-60. doi: 10.1016/j.ajpath.2010.12.042. Review.

17.

GPHMM: an integrated hidden Markov model for identification of copy number alteration and loss of heterozygosity in complex tumor samples using whole genome SNP arrays.

Li A, Liu Z, Lezon-Geyda K, Sarkar S, Lannin D, Schulz V, Krop I, Winer E, Harris L, Tuck D.

Nucleic Acids Res. 2011 Jul;39(12):4928-41. doi: 10.1093/nar/gkr014. Epub 2011 Mar 11.

18.

Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers.

Lamy PJ, Fina F, Bascoul-Mollevi C, Laberenne AC, Martin PM, Ouafik L, Jacot W.

Breast Cancer Res. 2011 Feb 2;13(1):R15. doi: 10.1186/bcr2824.

19.

Are current development programs realising the full potential of new agents?

Lønning PE.

Breast Cancer Res. 2010 Dec 20;12 Suppl 4:S23. doi: 10.1186/bcr2752. No abstract available.

20.

CEF is superior to CMF for tumours with TOP2A aberrations: a Subpopulation Treatment Effect Pattern Plot (STEPP) analysis on Danish Breast Cancer Cooperative Group Study 89D.

Gunnarsdóttir KA, Jensen MB, Zahrieh D, Gelber RD, Knoop A, Bonetti M, Mouridsen H, Ejlertsen B.

Breast Cancer Res Treat. 2010 Aug;123(1):163-9. doi: 10.1007/s10549-010-0931-y. Epub 2010 May 13.

Supplemental Content

Support Center